Sarepta Therapeutics, Inc. Files Definitive Proxy Statement (DEF 14A)

Ticker: SRPT · Form: DEF 14A · Filed: Apr 24, 2024 · CIK: 873303

Sentiment: neutral

Topics: Sarepta Therapeutics, SRPT, DEF 14A, Proxy Statement, Executive Compensation

TL;DR

<b>Sarepta Therapeutics, Inc. has filed its Definitive Proxy Statement (DEF 14A) detailing executive compensation and corporate governance matters.</b>

AI Summary

Sarepta Therapeutics, Inc. (SRPT) filed a Proxy Statement (DEF 14A) with the SEC on April 24, 2024. Sarepta Therapeutics, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 24, 2024. The filing pertains to the fiscal year ending December 31, 2023. The company's principal executive offices are located at 215 First Street, Suite 415, Cambridge, MA 02142. The business phone number listed is 617-274-4000. Sarepta Therapeutics, Inc. was incorporated in Delaware.

Why It Matters

For investors and stakeholders tracking Sarepta Therapeutics, Inc., this filing contains several important signals. This DEF 14A filing is crucial for shareholders to understand executive compensation structures and vote on important corporate matters at the upcoming annual meeting. The document provides insights into Sarepta's financial performance and strategic direction as reflected in executive pay and company proposals.

Risk Assessment

Risk Level: low — Sarepta Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement and does not contain new financial performance data or strategic shifts that would inherently increase risk.

Analyst Insight

Shareholders should review the executive compensation details and any proposed resolutions to make informed voting decisions.

Key Numbers

Key Players & Entities

FAQ

When did Sarepta Therapeutics, Inc. file this DEF 14A?

Sarepta Therapeutics, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 24, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Sarepta Therapeutics, Inc. (SRPT).

Where can I read the original DEF 14A filing from Sarepta Therapeutics, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Sarepta Therapeutics, Inc..

What are the key takeaways from Sarepta Therapeutics, Inc.'s DEF 14A?

Sarepta Therapeutics, Inc. filed this DEF 14A on April 24, 2024. Key takeaways: Sarepta Therapeutics, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 24, 2024.. The filing pertains to the fiscal year ending December 31, 2023.. The company's principal executive offices are located at 215 First Street, Suite 415, Cambridge, MA 02142..

Is Sarepta Therapeutics, Inc. a risky investment based on this filing?

Based on this DEF 14A, Sarepta Therapeutics, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement and does not contain new financial performance data or strategic shifts that would inherently increase risk.

What should investors do after reading Sarepta Therapeutics, Inc.'s DEF 14A?

Shareholders should review the executive compensation details and any proposed resolutions to make informed voting decisions. The overall sentiment from this filing is neutral.

How does Sarepta Therapeutics, Inc. compare to its industry peers?

Sarepta Therapeutics operates in the pharmaceutical preparations industry, focusing on developing and commercializing genetic, small molecule, and protein-based therapeutics.

Are there regulatory concerns for Sarepta Therapeutics, Inc.?

The filing is made under the Securities Exchange Act of 1934, which governs the reporting requirements for public companies regarding shareholder meetings and executive compensation.

Industry Context

Sarepta Therapeutics operates in the pharmaceutical preparations industry, focusing on developing and commercializing genetic, small molecule, and protein-based therapeutics.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, which governs the reporting requirements for public companies regarding shareholder meetings and executive compensation.

What Investors Should Do

  1. Review Sarepta's executive compensation packages and any related proposals.
  2. Understand the company's governance structure as outlined in the proxy statement.
  3. Prepare to vote on matters presented at the upcoming shareholder meeting.

Key Dates

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine disclosure for public companies and does not represent a change from previous filings of the same type.

Filing Stats: 4,697 words · 19 min read · ~16 pages · Grade level 12.9 · Accepted 2024-04-24 16:05:27

Key Financial Figures

Filing Documents

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 29 Compensation Discussion and Analysis 29 Introduction 29 I. 2023 Compensation Program Overview and Factors That Influenced 2023 Named Executive Officers' Compensation 29 II. 2023 Named Executive Officer Compensation 37 Detailed Analysis of 2023 Executive Compensation Program 37 Compensation Committee Report 44 Compensation Tables 45 III. Compensation Agreements for Named Executive Officers 57 CEO Pay Ratio 62 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 63 Approval of Related Party Transactions 63 Delinquent Section 16(a) Reports 63 Compensation Committee Interlocks and Insider Participation 63 ANNUAL REPORT 63 OTHER MATTERS 64 Forward-Looking Information This proxy statement contains forward-looking statements or incorporates by reference forward-looking statements. Statements that are not purely historical are forward-looking statements. Forward-looking statements are often identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may," "estimate," "could," "continue," "ongoing," "predict," "potential," "likely," "seek" and other similar expressions, as well as variations or negatives of these words. These statements address expectations, projections of future results of operations or financial condition, or other "forward-looking" information. These statements relate to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. These forward-looking statements include, but are not limited to the timing of our intended enhancements to ESG-related disclosures, the potential outcome and significance of future clinical trials, the timing of anticipated updates to our Board composition, and our intended treatment of future performance-based compensation. We undertake no obligation to update any of the forward-looking statements contained herein, except as required by law

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing